๐ Lumakras Breakthrough:
Amgen (AMGN) pioneers cancer treatment with Lumakras, the first medication targeting a mutation found in approximately 13% of lung cancer patients.
๐ฐ Strategic Acquisition:
Amgen acquires Horizon Therapeutics for a substantial $28 billion in cash.
Incorporates Tepezza, an FDA-approved medicine for thyroid eye disease, into Amgen's product portfolio.
๐ Market Outlook:
Bullish stance on AMGN suggests support levels above $260.00-$265.00.
Anticipated upside target in the range of $360.00-$365.00.
Exciting developments in biotech and strategic expansion for Amgen! ๐๐
#AmgenInnovation #Biotech #StockMarket ๐ฐ๐
Amgen (AMGN) pioneers cancer treatment with Lumakras, the first medication targeting a mutation found in approximately 13% of lung cancer patients.
๐ฐ Strategic Acquisition:
Amgen acquires Horizon Therapeutics for a substantial $28 billion in cash.
Incorporates Tepezza, an FDA-approved medicine for thyroid eye disease, into Amgen's product portfolio.
๐ Market Outlook:
Bullish stance on AMGN suggests support levels above $260.00-$265.00.
Anticipated upside target in the range of $360.00-$365.00.
Exciting developments in biotech and strategic expansion for Amgen! ๐๐
#AmgenInnovation #Biotech #StockMarket ๐ฐ๐
๋ฉด์ฑ ์ฌํญ
ํด๋น ์ ๋ณด์ ๊ฒ์๋ฌผ์ ๊ธ์ต, ํฌ์, ํธ๋ ์ด๋ฉ ๋๋ ๊ธฐํ ์ ํ์ ์กฐ์ธ์ด๋ ๊ถ์ฅ ์ฌํญ์ผ๋ก ๊ฐ์ฃผ๋์ง ์์ผ๋ฉฐ, ํธ๋ ์ด๋ฉ๋ทฐ์์ ์ ๊ณตํ๊ฑฐ๋ ๋ณด์ฆํ๋ ๊ฒ์ด ์๋๋๋ค. ์์ธํ ๋ด์ฉ์ ์ด์ฉ ์ฝ๊ด์ ์ฐธ์กฐํ์ธ์.
๋ฉด์ฑ ์ฌํญ
ํด๋น ์ ๋ณด์ ๊ฒ์๋ฌผ์ ๊ธ์ต, ํฌ์, ํธ๋ ์ด๋ฉ ๋๋ ๊ธฐํ ์ ํ์ ์กฐ์ธ์ด๋ ๊ถ์ฅ ์ฌํญ์ผ๋ก ๊ฐ์ฃผ๋์ง ์์ผ๋ฉฐ, ํธ๋ ์ด๋ฉ๋ทฐ์์ ์ ๊ณตํ๊ฑฐ๋ ๋ณด์ฆํ๋ ๊ฒ์ด ์๋๋๋ค. ์์ธํ ๋ด์ฉ์ ์ด์ฉ ์ฝ๊ด์ ์ฐธ์กฐํ์ธ์.
